Eisai Co. Ltd.

PNK: ESAIY · Real-Time Price · USD
7.16
-0.05 (-0.69%)
At close: May 01, 2025, 3:59 PM

Company Description

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.

It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer.

The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.

It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate.

Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.

Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Eisai Co. Ltd.
Eisai Co. Ltd. logo
Country JP
IPO Date Feb 2, 2023
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 11,067
CEO Haruo Naito

Contact Details

Address:
4-6-10, Koishikawa
Tokyo,
JP
Website https://www.eisai.co.jp

Stock Details

Ticker Symbol ESAIY
Exchange PNK
Fiscal Year April - March
Reporting Currency USD
CIK Code n/a
CUSIP Number 28258A107
ISIN Number US28258A1079
Employer ID -
SIC Code n/a

Key Executives

Name Position
Haruo Naito Chief Executive Officer, Representative Corporate Officer & Director
Keisuke Naito Representative Corporate Officer, EVice President, Chief Operating Officer & Chief Growth Officer
Makoto Hoketsu Vice President & Chief Information Officer
Mitsuru Shomon Vice President & Chief Financial Officer
Dr. Lynn D. Kramer FAAN, M.D. Vice President & Chief Clinical Officer
Gary Hendler Senior Vice President & President of EMEA Region
Katsutoshi Ido Vice President, Chief Scientific Officer & Head of DHBL Discoverry
Shin Kato Vice President, General Counsel & Chief Compliance Officer
Terushige Iike Executive Vice President, Rep. Corporate Officer and Chief IR Officer & Business Officer
Yanhui Feng Senior Vice President

Latest SEC Filings

No SEC filings available.